Loading clinical trials...
Loading clinical trials...
This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly. Patients with advanced solid tumors, who are refractory to available...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT06312137 · Non Small Cell Lung Cancer
NCT07586215 · Breast Cancer Metastatic
NCT06467357 · Biliary Tract Cancer
NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
NCT05831878 · Advanced Breast Cancer
Premiere Oncology
Santa Monica, California
Dana Farber/Harvard Cancer Center
Boston, Massachusetts
Mary Crowley Medical Research Center
Dallas, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions